Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE38.0400
- TODAY'S CHANGE (%)-0.3200 (-0.8342%)
- Bid / Lots35.0000/ 1
- Ask / Lots50.0000/ 1
- Open / Previous Close38.2500 / 38.3600
- Day Range
- 52 Week Range
- Volume300,462
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 676 | 38.25 |
| 09:39 ET | 1500 | 38.46 |
| 09:43 ET | 300 | 38.73 |
| 09:45 ET | 711 | 38.67 |
| 09:48 ET | 600 | 38.705 |
| 09:56 ET | 100 | 38.34 |
| 09:57 ET | 100 | 38.33 |
| 09:59 ET | 600 | 38.31 |
| 10:06 ET | 200 | 38.11 |
| 10:08 ET | 200 | 38.115 |
| 10:10 ET | 100 | 38.03 |
| 10:14 ET | 1297 | 38.06 |
| 10:15 ET | 198 | 38 |
| 10:17 ET | 1403 | 38.05 |
| 10:19 ET | 400 | 38.12 |
| 10:21 ET | 150 | 38.121 |
| 10:26 ET | 200 | 38.065 |
| 10:28 ET | 300 | 38.07 |
| 10:30 ET | 226 | 38.07 |
| 10:33 ET | 2247 | 37.985 |
| 10:35 ET | 1840 | 37.99 |
| 10:37 ET | 100 | 38 |
| 10:39 ET | 300 | 38.08 |
| 10:42 ET | 600 | 38.105 |
| 10:50 ET | 200 | 38.12 |
| 10:51 ET | 100 | 38.16 |
| 10:53 ET | 100 | 38.12 |
| 10:57 ET | 1000 | 38.19 |
| 11:00 ET | 900 | 38.195 |
| 11:02 ET | 100 | 38.21 |
| 11:04 ET | 200 | 38.25 |
| 11:06 ET | 2000 | 38.245 |
| 11:08 ET | 698 | 38.22 |
| 11:09 ET | 300 | 38.17 |
| 11:11 ET | 1700 | 38.19 |
| 11:13 ET | 400 | 38.185 |
| 11:15 ET | 273 | 38.19 |
| 11:18 ET | 800 | 38.17 |
| 11:20 ET | 800 | 38.115 |
| 11:22 ET | 100 | 38.115 |
| 11:24 ET | 2001 | 38.165 |
| 11:26 ET | 905 | 38.285 |
| 11:27 ET | 2674 | 38.22 |
| 11:29 ET | 700 | 38.26 |
| 11:31 ET | 1700 | 38.21 |
| 11:33 ET | 300 | 38.19 |
| 11:36 ET | 200 | 38.185 |
| 11:38 ET | 1000 | 38.11 |
| 11:40 ET | 300 | 38.07 |
| 11:42 ET | 475 | 38.07 |
| 11:44 ET | 100 | 38.075 |
| 11:45 ET | 1505 | 38.115 |
| 11:47 ET | 560 | 38.075 |
| 11:49 ET | 300 | 38.13 |
| 11:51 ET | 1200 | 38.14 |
| 11:54 ET | 300 | 38.165 |
| 11:56 ET | 520 | 38.16 |
| 12:02 ET | 400 | 38.14 |
| 12:03 ET | 1962 | 38.1 |
| 12:05 ET | 300 | 38.115 |
| 12:07 ET | 400 | 38.09 |
| 12:09 ET | 1200 | 38.06 |
| 12:14 ET | 646 | 38 |
| 12:16 ET | 949 | 38.03 |
| 12:18 ET | 400 | 38.035 |
| 12:20 ET | 915 | 38.04 |
| 12:21 ET | 400 | 38.03 |
| 12:23 ET | 1631 | 37.92 |
| 12:25 ET | 700 | 37.905 |
| 12:27 ET | 700 | 37.885 |
| 12:30 ET | 500 | 37.84 |
| 12:32 ET | 2985 | 37.86 |
| 12:34 ET | 1200 | 37.895 |
| 12:36 ET | 1000 | 37.9126 |
| 12:38 ET | 300 | 37.93 |
| 12:39 ET | 100 | 37.93 |
| 12:43 ET | 1205 | 37.94 |
| 12:45 ET | 901 | 37.99 |
| 12:52 ET | 400 | 38.04 |
| 12:54 ET | 1900 | 38.04 |
| 12:56 ET | 200 | 38.035 |
| 12:57 ET | 800 | 38.035 |
| 12:59 ET | 1600 | 38.03 |
| 01:01 ET | 900 | 38.025 |
| 01:03 ET | 2065 | 38.005 |
| 01:06 ET | 190 | 38.01 |
| 01:08 ET | 300 | 38 |
| 01:12 ET | 4159 | 38.12 |
| 01:14 ET | 944 | 38.04 |
| 01:15 ET | 500 | 38.065 |
| 01:17 ET | 100 | 38.065 |
| 01:19 ET | 100 | 38.06 |
| 01:21 ET | 300 | 38.065 |
| 01:24 ET | 306 | 38.065 |
| 01:26 ET | 200 | 38.06 |
| 01:30 ET | 100 | 38.045 |
| 01:32 ET | 2100 | 38.02 |
| 01:33 ET | 1470 | 38.02 |
| 01:35 ET | 1600 | 37.96 |
| 01:37 ET | 300 | 37.94 |
| 01:39 ET | 200 | 37.915 |
| 01:42 ET | 312 | 37.915 |
| 01:44 ET | 2386 | 37.93 |
| 01:46 ET | 2444 | 37.92 |
| 01:50 ET | 1200 | 37.9 |
| 01:51 ET | 1600 | 37.905 |
| 01:53 ET | 100 | 37.89 |
| 01:55 ET | 200 | 37.91 |
| 01:57 ET | 800 | 37.88 |
| 02:00 ET | 300 | 37.905 |
| 02:02 ET | 700 | 37.95 |
| 02:04 ET | 408 | 38 |
| 02:06 ET | 1800 | 37.97 |
| 02:08 ET | 200 | 37.97 |
| 02:11 ET | 1400 | 37.925 |
| 02:13 ET | 400 | 37.93 |
| 02:18 ET | 100 | 37.91 |
| 02:20 ET | 100 | 37.91 |
| 02:24 ET | 100 | 37.925 |
| 02:26 ET | 100 | 37.925 |
| 02:27 ET | 1152 | 37.91 |
| 02:29 ET | 2300 | 37.995 |
| 02:33 ET | 300 | 37.995 |
| 02:36 ET | 700 | 38.02 |
| 02:38 ET | 2000 | 38.03 |
| 02:40 ET | 2077 | 38.005 |
| 02:44 ET | 2100 | 37.98 |
| 02:45 ET | 200 | 37.99 |
| 02:47 ET | 500 | 37.92 |
| 02:49 ET | 200 | 37.92 |
| 02:51 ET | 1205 | 37.99 |
| 02:54 ET | 2715 | 38.05 |
| 02:58 ET | 3720 | 38.165 |
| 03:00 ET | 1467 | 38.135 |
| 03:02 ET | 1200 | 38.13 |
| 03:03 ET | 700 | 38.145 |
| 03:05 ET | 200 | 38.155 |
| 03:07 ET | 330 | 38.16 |
| 03:09 ET | 405 | 38.165 |
| 03:12 ET | 800 | 38.17 |
| 03:14 ET | 400 | 38.17 |
| 03:16 ET | 1100 | 38.165 |
| 03:18 ET | 4600 | 38.125 |
| 03:20 ET | 1900 | 38.105 |
| 03:21 ET | 1500 | 38.09 |
| 03:23 ET | 1199 | 38.06 |
| 03:25 ET | 3236 | 37.99 |
| 03:27 ET | 500 | 37.98 |
| 03:30 ET | 3250 | 38.06 |
| 03:32 ET | 200 | 38.05 |
| 03:34 ET | 2451 | 37.951 |
| 03:36 ET | 800 | 37.911 |
| 03:38 ET | 1986 | 37.975 |
| 03:39 ET | 500 | 37.975 |
| 03:41 ET | 800 | 37.96 |
| 03:43 ET | 1258 | 37.876 |
| 03:45 ET | 2905 | 37.86 |
| 03:48 ET | 3300 | 37.9 |
| 03:50 ET | 700 | 37.855 |
| 03:52 ET | 1900 | 37.88 |
| 03:54 ET | 2045 | 38 |
| 03:56 ET | 2900 | 38.08 |
| 03:57 ET | 4786 | 38.04 |
| 03:59 ET | 37119 | 38.04 |
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.0x | --- |
Structure Therapeutics Inc | 2.9B | -22.3x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.6x | --- |
MoonLake Immunotherapeutics | 2.8B | -56.9x | --- |
Biohaven Ltd | 3.0B | -4.9x | --- |
Geron Corp | 3.0B | -14.1x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
